Nortrel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nortrel

Quick Facts

Property Description
Active ingredient Norethindrone and Ethinyl Estradiol
Form Tablet (Oral Dosage Form)
Pharmacological class Sex Hormone Combination Contraceptive
Common use Prevention of pregnancy
Origin Synthetic

Nortrel: Identity and Pharmacological Classification

Nortrel is a prescription-only medication that belongs to the pharmacological class of Sex Hormone Combinations, delivered as an oral dosage form (tablet). Its defined therapeutic purpose is the reliable prevention of pregnancy in women who choose this method of contraception. The efficacy and safety profile of combination oral contraceptives supports its use as a primary contraceptive method. The medicine is utilized in a typical scenario when a patient seeks a long-term, reversible method of contraception.


Composition and Nature: Synthetic Estrogen and Progestin

The active compounds in Nortrel are norethindrone, a synthetic progestin, and ethinyl estradiol, a synthetic estrogen. This classification identifies Nortrel as a combination product because it incorporates both types of hormonal agents, setting it apart from progestin-only pills. These specific synthetic hormones are used for their ability to consistently inhibit ovulation. Other popular brands sharing this active ingredient profile include Ortho-Novum and Alyacen, which are all part of the same therapeutic category.


Understanding Nortrel's Formulation Types

The Nortrel product line offers variations categorized as either monophasic or triphasic formulations. This distinction relates only to the drug's internal structure: monophasic versions maintain a constant dose of both norethindrone and ethinyl estradiol throughout the active pill cycle. Conversely, triphasic versions alter the dose across three distinct periods, a design feature intended to more closely track natural hormonal fluctuations. This differentiation allows for tailoring the hormone delivery schedule to individual needs while maintaining the same core contraceptive function.

Regulatory References

  1. Ethinyl Estradiol and Norethindrone (Oral Contraceptives)
  2. NORTREL 7/7/7 (28 DAY REGIMEN) Drug Label

What side effects are possible with Nortrel?

Possible Side Effects and Safety Information

The safety profile of combination oral contraceptives like Nortrel (Norethindrone and Ethinyl Estradiol) is characterized by a spectrum of officially documented adverse reactions, categorized by their frequency and the organ systems affected.


Frequency-Classified Adverse Reactions

Adverse reactions are formally classified based on the likelihood of their occurrence, as defined in regulatory documents. Common reactions (occurring in 1% to less than 10% of users) generally include headache, nausea or vomiting, breast pain or tenderness, and breakthrough bleeding (bleeding outside the scheduled withdrawal bleed). Effects such as fluid retention and migraine are often classified as uncommon.


Systemic and Serious Adverse Reactions

Side effects are categorized by the System-Organ Class they affect, including Reproductive System and Breast Disorders and Nervous System Disorders. The most critical safety component explicitly documented in official regulatory labeling is the risk of serious thromboembolic events, which are classified as rare. These serious risks include Venous Thromboembolism (e.g., Deep Vein Thrombosis) and Arterial Thromboembolism (e.g., Stroke or Myocardial Infarction).


Safety Constraints and Time Patterns

The regulatory profile mandates specific contraindications, prohibiting use in individuals with a history of thrombotic events, severe hepatic impairment, or uncontrolled hypertension. A documented time-related pattern exists where irregular bleeding, such as spotting, is explicitly noted to be more common during the first few cycles of treatment as the body adjusts to the hormones. Furthermore, official labeling highlights that smoking in women over 35 years of age significantly increases the risk of serious cardiovascular events.

Overdose and Emergency Response

Overdose Scope

The most consistently documented overdose manifestations in regulatory guidance are Nausea, Vomiting, and Withdrawal Bleeding (Vaginal Bleeding). These effects primarily involve the gastrointestinal and reproductive/endocrine systems. Overdose is associated with the ingestion of doses higher than prescribed, including accidental ingestion.

Official Emergency Actions

Official regulatory sources mandate that users seek emergency medical attention immediately or call a poison control center at once (e.g., 1-800-222-1222). Urgent medical assistance must be sought for any suspected overdose or if serious symptoms, such as loss of consciousness, occur.

Overdose Classification and Management

Regulatory documentation states that overdose of this product class is generally not likely to be life-threatening, and reports of serious ill effects are not expected. The required management strategy is confined to symptomatic and supportive measures because no specific antidote is known for this overdose. Monitoring in an emergency setting may include observation of vital signs and specific laboratory (blood and urine) tests.

Therapeutic Uses of Nortrel

What Nortrel Treats: Main Uses and Benefits

Nortrel is utilized across several key therapeutic domains to provide symptomatic management and patient benefits beyond its primary role in preventing pregnancy. Its clinical applications are focused on symptom management related to systemic imbalance in women of reproductive age.

Its applications focus on alleviating pronounced symptom clusters that create noticeable interference with daily stability. The medication is commonly used to help manage the symptomatic profile of conditions like Polycystic Ovary Syndrome (PCOS), and is relevant for easing the burden of unusually heavy menstrual bleeding (menorrhagia) and severe menstrual pain (dysmenorrhea). It also addresses symptoms linked to androgen excess, such as moderate acne vulgaris, and is applied in contexts where patients require assistance in regulating erratic cycles.

“The goal is to provide supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

By addressing these issues, Nortrel contributes to improved day-to-day comfort and may support the development of a predictable bleeding pattern.

Quick Fact: Relief for Pain and Bleeding
This combination medicine is often used during phases when menstrual symptoms become more noticeable, helping to reduce the severity of painful cramping and excessive blood loss associated with monthly cycles.

Regulatory References

  1. NIH DailyMed overview for this class of medicine

Eligibility and Restrictions for Use

Nortrel (norethindrone and ethinyl estradiol) is contraindicated in certain populations due to the risk of serious side effects, primarily related to cardiovascular events and specific medical conditions. These contraindications are mandated by regulatory agencies, such as the FDA, to define the non-eligible population.

Populations Excluded from Use (Contraindicated)

Condition / Population Exclusion Status
Smokers over age 35 Contraindicated (High cardiovascular risk)
Known or suspected pregnancy Contraindicated (Must discontinue use)
Current or history of breast cancer Contraindicated (Hormone-sensitive cancer)
Thrombotic disorders (DVT, PE, stroke, heart attack) Contraindicated (High risk of recurrence)
Active liver disease or liver tumors Contraindicated (Impaired hormone metabolism)
Uncontrolled hypertension or Diabetes with vascular disease Contraindicated (Cardiovascular risk factors)

Populations with Restricted or Limited Use

  • Postpartum Women (Non-breastfeeding): Use must not start earlier than 4 weeks after delivery due to heightened risk of blood clots during the postpartum period.
  • Lactation/Breastfeeding: Nortrel is not generally recommended as combined hormonal contraceptives may decrease the quality and quantity of breast milk.
  • Pediatric Use: The medication is indicated for use by females who have started having menstrual periods (post-menarche).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Nortrel (Norethindrone/Ethinyl Estradiol), focusing strictly on regulatory findings regarding co-administration.

Classification Description
Severity Contraindicated, Diminished Efficacy, Significant Change in Plasma Concentration.
Regulatory Basis FDA Prescribing Information / DailyMed.
Restrictions Contraindicated with ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Official Interaction Statements:

  • Enzyme Inducers: Co-administration with medicinal products or herbal supplements that induce CYP3A4 activity, such as phenytoin, rifampicin, carbamazepine, and St. John’s wort, may lead to a decrease in the plasma concentrations of Nortrel’s hormonal components. This interaction is formally documented to reduce contraceptive effectiveness.
  • Contraindicated Combinations: Co-administration with the Hepatitis C virus (HCV) drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is prohibited due to the formal risk of significant ALT enzyme elevations.
  • Exposure Modification: Drugs that inhibit CYP3A4 (e.g., fluconazole, itraconazole) or inhibit conjugation (e.g., Ascorbic acid) may increase the plasma concentrations of the Ethinyl Estradiol component.
  • Timing Separation: The bile acid sequestrant colesevelam significantly decreases the exposure (AUC) of Ethinyl Estradiol; this interaction is reduced when the two products are administered four hours apart.
  • Effect on Other Drugs: Nortrel may inhibit the metabolism of co-administered compounds (e.g., cyclosporine, prednisolone) and may decrease the plasma concentration of lamotrigine.

Connection to the overall interaction profile: The official profile is defined by pharmacokinetic interactions involving hepatic enzyme metabolism (CYP3A4) that alter hormone exposure, which is formally linked to potential contraceptive failure. The profile also mandates a contraindication with certain Hepatitis C virus drug combinations due to the documented risk of severe liver enzyme elevation.

Mechanism of Action

Nortrel, a combination hormonal formulation, exerts its effects via the synthetic progestin norethindrone and the synthetic estrogen ethinyl estradiol.

These steroidal compounds interact primarily as agonists at the intracellular progesterone and estrogen receptors in target tissues, including the hypothalamus, pituitary gland, ovaries, cervix, and endometrium. Systemic administration modulates the hypothalamic-pituitary-ovarian axis.

Specifically, the exogenous hormones induce negative feedback on the hypothalamus and pituitary, resulting in the suppression of gonadotropin release, namely Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This cascade prevents the mid-cycle LH surge, which is the primary molecular and cellular event required for the release of an oocyte from the ovary. This inhibition of oocyte release is the dominant physiological consequence.

Simultaneously, the drug-receptor interaction in the lower reproductive tract induces secondary, localized effects. Norethindrone causes the cervical glands to produce a viscous, impenetrable cervical mucus, which physically impedes sperm migration into the upper female reproductive tract. In the endometrium, the combined hormonal action causes cellular and vascular changes, rendering the tissue unreceptive to blastocyst nidation.

Dosage and Administration Information

Nortrel is a medicine administered orally in tablet form, with usage defined by a standardized 28-day cyclic protocol. The official dosing schedule involves taking one active tablet once daily at the same time each day, following a 24-hour interval.

The product is available in formulations classified as either monophasic, where the dose of norethindrone and ethinyl estradiol remains constant across the 21 active days, or triphasic, where the active dose changes in three distinct sequences. Available active strengths include combinations such as 0.5 mg/0.035 mg and 1 mg/0.035 mg. Each 28-day course consists of 21 active tablets, followed by a seven-day interval containing either reminder tablets or no tablets, after which a new cycle is immediately initiated.

Administration may occur with or without food, though labeling suggests taking the tablet after an evening meal or at bedtime may assist patients with sensitive stomachs. Regardless of the regimen, tablets must be taken sequentially in the order indicated on the package. The labeling provides specific, detailed procedural instructions for handling missed active tablets, which can include temporary reliance on a non-hormonal back-up contraceptive method. Furthermore, if severe vomiting or diarrhea occurs within three to four hours of taking an active tablet, the event is managed procedurally as a missed dose. The use of this combination product is established for females who have attained menarche.

Recent Clinical Evidence

Nortrel: Recent Clinical Evidence

Nortrel is a fixed-dose oral contraceptive combining the synthetic progestin norethindrone and the synthetic estrogen ethinyl estradiol. Clinical research focuses primarily on its use for the prevention of pregnancy.

Contraceptive Efficacy

Contraceptive efficacy is evaluated in clinical trials using the Pearl Index (PI), which measures the number of unintended pregnancies per 100 women years of use. For combined oral contraceptives (COCs) containing similar doses of norethindrone and ethinyl estradiol, the efficacy rates in studies indicate a high degree of effectiveness when taken consistently and correctly.

  • Typical Use: Studies suggest that failure rates in typical use (which includes variations in adherence) are higher than in perfect use.
  • Perfect Use: When taken precisely as directed, the failure rate observed in clinical settings is significantly lower, demonstrating the potential for reliable contraception.

Non-Contraceptive Health Benefits

Beyond contraception, clinical data and long-term observational studies suggest hormonal regulation may be associated with secondary health benefits. These observed effects include:

Observed Effect Clinical Observation
Cycle Regularity Increased regularity of menstrual cycles.
Menses Flow Decreased menstrual blood loss and incidence of anemia related to blood loss.
Dysmenorrhea Decreased incidence and severity of menstrual pain.

Safety and Tolerability Profile

Trial data on combined oral contraceptives generally indicate a consistent safety profile. Common adverse effects frequently reported in clinical studies include headache, nausea, and breast tenderness. Serious adverse events, such as thromboembolic events (blood clots), are rare but represent a known risk that is consistently monitored in clinical practice and post-marketing surveillance. Research highlights that the risk of serious morbidity or mortality remains very small in healthy individuals without pre-existing risk factors.

Key Studies & References

  1. Label: NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE kit - FDA DailyMed
  2. Combined birth control pills and health benefits beyond contraception (Systematic Review/Guideline Source)
  3. ACOG Practice Bulletin on Combined Hormonal Contraceptives in Women with Coexisting Medical Conditions (Source for safety/risk profile)

Frequently Asked Questions (FAQ)

Common questions about Nortrel (FAQ)

Q: Is it true that Nortrel can affect mood or cause emotional changes?

A: Official product information indicates that mood changes, mood swing, depression, and anxiety have been listed as adverse reactions in clinical trial data. It is also noted that official documents recommend that individuals with a history of depression be carefully observed by a healthcare provider.

Q: Can Nortrel cause changes to a person's skin or hair?

A: Official regulatory documents mention skin-related effects such as acne and dark patches of skin on sun-exposed areas (chloasma) as reported adverse events. While hair loss or thinning is not consistently listed as a common effect in primary clinical data, changes in skin color are officially documented.

Q: Does Nortrel typically lead to changes in appetite?

A: According to postmarketing regulatory data, changes in appetite have been reported, specifically increased appetite and decreased appetite. These effects are noted in official sources with incidence not always known in the primary clinical trials.

Q: Can Nortrel affect sleep patterns or cause insomnia?

A: Official documentation lists insomnia (trouble sleeping) as an adverse event reported in postmarketing surveillance. Additionally, the feeling of tiredness (fatigue) has also been reported in regulatory documents, though its frequency is not consistently provided.

Q: Is feeling generally tired a typical experience with Nortrel?

A: Regulatory documents list the general feeling of being unwell (malaise) and fatigue as adverse events associated with the use of the drug. Fatigue is listed in some official labels, but the exact frequency is not always reported.

Q: Are there specific activities or types of work to consider regarding Nortrel side effects?

A: Regulatory patient counseling information states that individuals who wear contact lenses and experience visual changes or difficulty wearing their lenses may require attention. Official labeling indicates that an ophthalmologic assessment may be warranted in these situations.

Q: Can I take Nortrel with regular pain relievers?

A: Official regulatory information lists acetaminophen as one medication that may interact with the hormonal components of Nortrel. Because of potential interactions, official information suggests that all co-administered medications, including common over-the-counter pain relievers, should be discussed with a healthcare provider.

Q: Are there any foods or beverages that should be avoided when using Nortrel?

A: Official documents state that consumption of grapefruit juice is not recommended while using Nortrel. This is because grapefruit juice consumption may lead to an increase in the plasma concentrations of the hormonal components in the body.

Q: How does alcohol consumption potentially interact with Nortrel?

A: While official labeling does not detail a direct pharmacological interaction with alcohol, there is a warning concerning heavy drinking. If heavy drinking leads to vomiting within three to four hours of taking an active tablet, official guidance addresses the procedural management of vomiting, where it is considered equivalent to a missed dose.

Q: How long does it typically take for Nortrel to start showing its expected effect?

A: The official product information explains that contraceptive protection may begin immediately if the first tablet is initiated on Day 1 of the menstrual cycle. If the product is started on Day 5, official instructions recommend the use of a non-hormonal back-up method (such as condoms) for the first seven days to support contraceptive efficacy.

Q: Do the effects of Nortrel on the body last all day?

A: The official dosing schedule describes taking one active tablet once daily at the same time each day. This required daily administration is intended to ensure consistent and adequate hormone levels are maintained in the body over the 24-hour period.

Q: Can older adults use Nortrel safely, or are there special considerations?

A: The most critical age-related safety contraindication in official labeling is the use of combined hormonal contraceptives by women over the age of 35 who smoke. This combination significantly increases the risk of serious cardiovascular events.

Q: Is Nortrel classified as a controlled substance?

A: According to official regulatory bodies, Nortrel (norethindrone/ethinyl estradiol) is a prescription-only medication. However, it is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: What is the typical timeframe for seeing the full benefits of Nortrel?

A: For contraceptive efficacy, the timeframe depends on the starting day of the menstrual cycle. For non-contraceptive benefits, such as improved cycle regularity or decreased pain, these effects are generally observed over the first few cycles of continuous use.

Q: Can Nortrel affect the results of standard lab tests?

A: Official labeling includes a warning that hormonal contraceptives may affect the results of certain standard laboratory tests. These can include tests related to thyroid function, coagulation factors, lipid metabolism, and glucose tolerance.

How should Nortrel be stored and disposed of?

Storage and Disposal Instructions for Nortrel

Nortrel (norethindrone and ethinyl estradiol tablets) must be stored at Controlled Room Temperature, which is defined by regulatory agencies as between 20 C to 25 C (68 F to 77 F). Permitted temperature excursions for brief periods range from 15 C to 30 C (59 F to 86 F). The medication must be kept in its original container and stored out of the reach of children.

For disposal of expired or unused medication, patients should primarily utilize a drug take-back program. If one is not available, the tablets can be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a plastic bag, and placed in the household trash. Do not flush Nortrel down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nortrel found in:

A-Z Index: